Form 4: Wave Life Sciences Director Adjusts Holdings

Wave Life Sciences Director Christian Henry reported acquiring restricted stock units and options, while also selling a portion of his ordinary shares under a pre-arranged trading plan.

Summary

• Christian O. Henry, a Director of Wave Life Sciences Ltd. (WVE), reported changes in his beneficial ownership of company securities.
• On August 11, 2025, Henry was granted 12,700 Ordinary Shares as a Restricted Share Unit (RSU) award at a price of $0.00, pursuant to the 2025 Non-Employee Director Compensation Policy.
• This RSU award vests 100% on the earlier of the Company's 2026 annual general meeting or August 11, 2026.
• On August 11, 2025, Henry was also granted 76,200 Share Options with an exercise price of $8.105, pursuant to the 2025 Non-Employee Director Compensation Policy.
• These options vest 100% on the earlier of the Company's 2026 annual general meeting or August 11, 2026, and expire on August 11, 2030.
• On August 13, 2025, Henry sold 9,670 Ordinary Shares at a weighted-average sale price of $8.81 per share.
• The sales were executed under a Rule 10b5-1 trading plan adopted by Henry on November 24, 2024.
• The sale prices for these transactions ranged from $8.45 to $9.03 per share.
• Following these transactions, Henry beneficially owns 29,645 Ordinary Shares directly and 76,200 Share Options directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there is insider selling, it was pre-planned under a 10b5-1 plan, mitigating negative interpretations. The grants of RSUs and options represent standard compensation and align the director's interests with the company's future performance.

Positives

• The grant of 12,700 Restricted Share Units and 76,200 Share Options aligns the director's long-term interests with those of the shareholders, as these awards vest over time and are tied to company performance or continued service.

Negatives

• The sale of 9,670 Ordinary Shares by a director, even if pre-planned, reduces their direct equity stake in the company.

Future Outlook

The Restricted Share Units and Share Options granted to the director are scheduled to vest on the earlier of the Company's 2026 annual general meeting or August 11, 2026, indicating a future milestone for these compensation awards.

Industry Context

This Form 4 filing provides transparency into an insider's transactions, which is a standard regulatory disclosure. It does not offer broader industry context or trends.

Corporate Governance

Related Party Transactions

• Grant of 12,700 Restricted Share Units to Director Christian Henry as part of the 2025 Non-Employee Director Compensation Policy.
• Grant of 76,200 Share Options to Director Christian Henry as part of the 2025 Non-Employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: Provides transparency regarding director stock ownership changes and compensation, which can influence perceptions of insider confidence and alignment.

Next Steps

• Vesting of 12,700 Restricted Share Units on the earlier of the Company's 2026 annual general meeting or August 11, 2026.
• Vesting of 76,200 Share Options on the earlier of the Company's 2026 annual general meeting or August 11, 2026.

Key Dates

Keywords

Wave Life Sciences, WVE, Form 4, Insider Trading, Director Compensation, Restricted Share Units, Stock Options, Rule 10b5-1 Plan, Share Sale, Beneficial Ownership